Lisen Medicine and Galixir Announce Significant Progress in 'Imprinted Genes + AI' Drug Pipeline and Sign Agreement to Deepen Strategic Collaboration

On November 1, the Lisen Pharma & Xingyao Tech Achievements Launch Event and Deepened Cooperation Signing Ceremony was held in Shanghai, with representatives from Zhangjiang Pharma Valley Platform and Merck China Innovation Center in attendance. At the event, both parties announced significant milestone progress in their jointly developed innovative drug project for lung cancer and formally signed an agreement to deepen their collaboration, ushering in a new chapter in “imprinted gene + artificial intelligence”-driven drug development.

Lisen and Xingyao forged their partnership through the Merck China Innovation Center Accelerator Program. Building on mutual recognition of each other’s technologies, the two parties joined forces and officially signed an agreement in November 2020 to jointly develop innovative drugs for lung cancer. This event, comprising both the announcement of key milestone achievements and the signing ceremony for deepened collaboration, aims to unveil the project’s significant interim results and formalize an expanded partnership across additional indications.

At the press conference, both parties statedThe collaborative development project for innovative lung cancer drugs is a process of technological complementarity and integration of strengths between both parties.Lisen identifies distinct biological phenotypes using its proprietary epigenetic imprinting technology to pinpoint key targets for drug design. Xingyao Tech leverages cutting-edge artificial intelligence for small-molecule drug design, enabling the efficient discovery of promising compound molecules.

At the conference, both parties announced that they had identified candidate drugs with high potency capable of overcoming drug resistance., this drug holds promise for bringing new hope to patients with small cell lung cancer and those who are resistant to existing treatment regimens. Moving forward, both parties will further collaborate to advance the subsequent development of this drug, striving for its early entry into clinical trials and market launch.

Meanwhile, both parties announced that they would expand new collaborative projects on the basis of continuing to advance the current project, engage in extensive cooperation across more indications, further deepen the strategic layout of “imprinted genes + artificial intelligence,” and formally sign an agreement to deepen their collaboration.

Both parties will continue to integrate their respective strengths in biological research, pathogenesis, drug design, molecular optimization, and cellular assays, actively advancing the innovative application of “imprinted genes + artificial intelligence” in drug development. By examining the contemporary challenges of innovative drug discovery and translation through the novel lenses of biological research and machine learning, they aim to address unmet clinical needs.

Regarding this collaboration, Dr. Zhou Ning, Founder and CEO of Lisen, stated:“Lisen’s partnership with Merck has forged a strong connection with Xingyao Pharmaceutical. Through mutual promotion and support in the R&D of innovative lung cancer therapeutics, we have achieved significant progress and sparked new opportunities. This has further strengthened our confidence in Xingyao’s technological capabilities in AI-driven small molecule design and optimization. We look forward to continuing our collaboration with Xingyao to achieve even greater milestones. We are delighted to deepen our cooperation with Xingyao and believe that combining Xingyao’s AI technology with our proprietary Imprint Gene Technology will enable the development of new blockbuster drugs.”

Dr. Li Chengtao, Founder & CEO of Xingyao Technology, stated:“We are delighted to establish a more comprehensive and in-depth partnership with Lisen. Our collaboration on innovative lung cancer drug projects has been highly productive, yielding significant milestone achievements. This success demonstrates the strong complementarity and synergy between Lisen’s imprinting gene technology and our AI-driven drug development platform. We look forward to expanding our cooperation with Lisen across broader areas, leveraging our respective industry expertise and integrated advantages to accelerate the R&D of more high-quality innovative medicines, ultimately alleviating patient suffering.”

Shanghai Lisen Yinji Pharmaceutical Technology Co., Ltd., established in June 2021, is a technology-driven enterprise dedicated to the development of innovative oncology drugs by monitoring epigenetic states. Leveraging its proprietary quantitative epigenetics technology, Lisen Pharmaceutical accurately maps the network of relationships among malignant tumor phenotypes, targeted therapy signaling pathways, and epigenetic biomarkers. The company has developed data models capable of accurately predicting clinical efficacy based on epigenetic biomarkers, thereby significantly enhancing the efficiency of in vitro compound screening.

Lisen Pharma focuses on addressing clinical pain points by targeting the reversal of epigenetic states, and is currently dedicated to developing innovative drugs for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) with resistance to targeted therapies. Leveraging its proprietary epigenetic biomarker drug development platform, Lisen Pharma provides a new perspective for the research and development of innovative anti-tumor drugs.

Galixir, founded in 2019, is a company that leverages cutting-edge artificial intelligence technologies to empower drug discovery and development. By employing advanced AI algorithms and integrating tools and expertise from computational chemistry, medicinal chemistry, and biology, Galixir comprehensively addresses the challenging issues in the early stages of small-molecule drug development, enabling the rapid identification of novel candidate molecules with high potency and favorable druggability.

Xingyao is collaborating with pharmaceutical companies and research institutions both in China and abroad to advance multiple drug development pipelines, covering various therapeutic areas such as central nervous system disorders, autoimmune diseases, oncology, and respiratory diseases. The mechanisms of action include diverse classes such as inhibitors and agonists. Xingyao has significantly reduced the cost and timeline of individual preclinical drug development pipelines, making it feasible to maintain a robust portfolio of multiple drug candidates and optimize its overall strategic layout.